This Plain Language Summary of publication article (PLSP) from Future Oncology presents findings from the ARCHES and ENZAMET follow-up studies, which investigated the effectiveness of enzalutamide in treating metastatic hormone-sensitive prostate cancer (mHSPC). The ARCHES study compared enzalutamide combined with androgen deprivation therapy (ADT) to a placebo with ADT, while the ENZAMET study compared enzalutamide plus ADT to standard treatment with ADT, with some participants also receiving docetaxel (a chemotherapy). Both studies aimed to determine whether enzalutamide improves survival in patients with mHSPC.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer’ and was published in The Journal of Clinical Oncology and ‘Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial’ and was published in The Lancet Oncology.

Visit ASCO Publications using the link to read the original article.

Visit The Lancet using the link to read the original article.